Boehringer Ingelheim and Vanderbilt University Join Forces to Develop New Ras Inhibitors for Cancer Treatment

INGELHEIM, Germany. – Wednesday, January 14th 2015 [ME NewsWire]

(BUSINESS WIRE) Boehringer Ingelheim announced today that it has established a research alliance with Vanderbilt University and the cancer medicine discovery laboratory of Professor Stephen W. Fesik, Ph.D., the Orrin H. Ingram, II Chair in Cancer Research and Professor of Biochemistry, Pharmacology, and Chemistry. The final cause of the new collaboration is the inquiry and development of small molecule inhibitors of oncogenic Ras because of the treatment of cancer. Ras is the ~ numerous frequently mutated oncogene known in cancer through K-Ras being the most commonly mutated shape occurring in pancreas, colon, biliary parcel and lung adenocarcinomas. Mutations in the Ras clan (comprised of H-Ras, N-Ras and K-Ras) are exceedingly common, and found in 20 to 30 percent of altogether human tumors. Ras has been a singly difficult protein to target since its first view in human cancers more than 30 years gone.
Under the terms of the agreement, the investigation capabilities of Vanderbilt University and Boehringer Ingelheim resoluteness be brought together in a multi-year careful search programme focusing on the development of inconsiderable molecule inhibitors of Ras. Further distinct parts of the agreement are not disclosed.
“We are looking hasten to working together with Professor Fesik and his team at Vanderbilt University to show new medicines for the Ras protein household,” said Michel Pairet, M.D., Senior Corporate Vice President of Research and Non-clinical Development at Boehringer Ingelheim. “We make no doubt of that our combined strengths and philosophies in medicine discovery will go a long path in addressing what has up to a little while ago been a very difficult drug target.”
“Dr. Fesik is a pioneer in the first view of small molecules that bind to and stop challenging drug target proteins. The association of his lab’s novel techniques and the pecuniary means and expertise of Boehringer Ingelheim command result in a powerful drug discovery team,” said Lawrence J. Marnett, Ph.D., the Mary Geddes Stahlman Professor of Cancer Research, University Professor of Biochemistry and Chemistry, and newly appointed fraternize vice chancellor for Research for the Vanderbilt University Medical Center.
http://www.boehringer-ingelheim.com/recent accounts/news_releases/press_releases/2015/14_january_2015_collaboration.html

Contacts
Boehringer Ingelheim
Dr. Reinhard Malin
Corporate Communications – Oncology, and Pipeline
Phone: +49 (6132) 77-90815
email: reinhard.malin@boehringer-ingelheim.com

Permalink: http://me-newswire.unadulterated/news/13365/en

Vogue profiled her like a “Rose in the Desert,” through her Chanel necklace and Louboutin silk handbag.

Search keywords

Recent Comments

    Archives